DSpace Arşivi :: by Yazar "Karabulut, Bulent" değerine göre listeleniyor

Listeleniyor 1 - 2 / 2

Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.
(Lippincott Williams & Wilkins, 2021) Kefeli, Umut; Arslan, Cagatay; Yildirim, Mahmut Emre; Isikdogan, Abdurrahman; Karadurmus, Nuri; Karabulut, Bulent; Cubukcu, Erdem
[Abstract Not Available]
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
(Future Medicine Ltd, 2022) Ozet, Ahmet; Dane, Faysal; Aykan, Nuri Faruk; Yalcin, Suayib; Evrensel, Turkkan; Ozkan, Metin; Karabulut, Bulent
Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.